These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7981903)

  • 1. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.
    Doglioni C; Dei Tos AP; Laurino L; Chiarelli C; Barbareschi M; Viale G
    Virchows Arch; 1994; 424(1):47-51. PubMed ID: 7981903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA; Carlson DL; Horenstein MG; Osborne MP
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
    Coradini D; Pellizzaro C; Veneroni S; Ventura L; Daidone MG
    Br J Cancer; 2002 Nov; 87(10):1105-11. PubMed ID: 12402149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
    Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
    Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas.
    Frolik D; Caduff R; Varga Z
    Histopathology; 2001 Nov; 39(5):503-13. PubMed ID: 11737309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.
    Leek RD; Kaklamanis L; Pezzella F; Gatter KC; Harris AL
    Br J Cancer; 1994 Jan; 69(1):135-9. PubMed ID: 8286195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables.
    Binder C; Marx D; Overhoff R; Binder L; Schauer A; Hiddemann W
    Ann Oncol; 1995 Dec; 6(10):1005-10. PubMed ID: 8750153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.
    Gee JM; Robertson JF; Ellis IO; Willsher P; McClelland RA; Hoyle HB; Kyme SR; Finlay P; Blamey RW; Nicholson RI
    Int J Cancer; 1994 Dec; 59(5):619-28. PubMed ID: 7960234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining.
    Nakopoulou L; Michalopoulou A; Giannopoulou I; Tzonou A; Keramopoulos A; Lazaris AC; Davaris PS
    Histopathology; 1999 Apr; 34(4):310-9. PubMed ID: 10231398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
    Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas.
    Luna-Moré S; de los Santos F; Bretón JJ; Cañadas MA
    Pathol Res Pract; 1996 Jan; 192(1):27-32. PubMed ID: 8685038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
    Albonico G; Querzoli P; Ferretti S; Rinaldi R; Nenci I
    Cancer Detect Prev; 1998; 22(4):313-8. PubMed ID: 9674874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.
    Bhargava V; Kell DL; van de Rijn M; Warnke RA
    Am J Pathol; 1994 Sep; 145(3):535-40. PubMed ID: 8080038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. bcl-2 expression in the spectrum of preinvasive breast lesions.
    Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
    Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of c-erbB3 protein in primary breast carcinomas.
    Naidu R; Yadav M; Nair S; Kutty MK
    Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
    Moran MS; Yang Q; Haffty BG
    Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.